Kiniksa CEO Sanj K Patel’s Stock Sales Reach $51.7 Million Since August 8

Wednesday’s $14.3 million sale came under a pre-scheduled trading plan; Patel retains 976,643 shares through trusts.

Share
Kiniksa CEO Sanj K Patel’s Stock Sales Reach $51.7 Million Since August 8

Sanj K Patel, chairman and CEO of Kiniksa Pharmaceuticals International, which develops and sells therapies focused on heart and blood vessel diseases, sold $14.3 million of company stock Wednesday, according to an SEC filing submitted Friday. The transaction brings his sales since August 8 to 553,794 shares worth $51.7 million.

Options Exercised, Shares Sold

Patel sold 151,300 shares at an average price of $94.71. The trades were made under a pre-scheduled trading plan he adopted on July 30, 2026.

Wednesday’s activity also included an option exercise for 145,763 shares at $17.92 apiece. Those options were fully vested, and the shares were held through The Anglia 2013 Revocable Trust. That trust held 774,500 shares after the transactions.

Across his trusts, Patel retains 976,643 shares, with his holdings entirely indirect. Those shares were worth approximately $91.7 million at Friday’s close.

An Earlier $37.4 Million Sale

The Wednesday transaction follows Patel’s October 30 sale of 402,494 shares for $37.4 million, at an average price of approximately $92.92. His SEC trading reports covering the period beginning August 8 show two sale filings, including the latest one.

KNSA shares closed Friday at $93.86, compared with Wednesday’s average sale price of $94.71. The stock had gained about 114% this year as of Thursday’s close.

ARCALYST Anchors Kiniksa’s Business

Kiniksa’s only commercial drug is ARCALYST, a weekly injection approved in the United States for recurrent pericarditis—painful inflammation around the heart—and the rare inflammatory conditions CAPS and DIRA.

The company has sold ARCALYST through its specialty sales force since March 2021, with patients supplied by a select group of specialty pharmacies. Regeneron licenses the drug to Kiniksa, manufactures it and splits its profits evenly with the company. Hangzhou Zhongmei Huadong Pharmaceutical holds Asia Pacific rights outside Japan.

Kiniksa’s experimental antibody pipeline includes KPL-387, in mid-stage testing for recurrent pericarditis, and KPL-1161, which remains in preclinical development.

Sources

More on Kiniksa Pharmaceuticals International

All Kiniksa Pharmaceuticals International (KNSA) coverage →